PL2137655T3 - Zdefiniowane produkty glikoproteinowe i powiązane sposoby - Google Patents

Zdefiniowane produkty glikoproteinowe i powiązane sposoby

Info

Publication number
PL2137655T3
PL2137655T3 PL08754908T PL08754908T PL2137655T3 PL 2137655 T3 PL2137655 T3 PL 2137655T3 PL 08754908 T PL08754908 T PL 08754908T PL 08754908 T PL08754908 T PL 08754908T PL 2137655 T3 PL2137655 T3 PL 2137655T3
Authority
PL
Poland
Prior art keywords
related methods
glycoprotein products
defined glycoprotein
products
methods
Prior art date
Application number
PL08754908T
Other languages
English (en)
Inventor
Ganesh Venkataraman
Brian Edward Collins
Carlos J Bosques
Lakshmanan Thiruneelakantapillai
Dorota A Bulik
Ian Christopher Parsons
Zachary Shriver
Rajeev Chillakuru
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of PL2137655T3 publication Critical patent/PL2137655T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Bioethics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08754908T 2007-04-16 2008-04-15 Zdefiniowane produkty glikoproteinowe i powiązane sposoby PL2137655T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91210207P 2007-04-16 2007-04-16
EP08754908A EP2137655B1 (en) 2007-04-16 2008-04-15 Defined glycoprotein products and related methods
PCT/US2008/060354 WO2008128227A1 (en) 2007-04-16 2008-04-15 Defined glycoprotein products and related methods

Publications (1)

Publication Number Publication Date
PL2137655T3 true PL2137655T3 (pl) 2012-12-31

Family

ID=39553226

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08754908T PL2137655T3 (pl) 2007-04-16 2008-04-15 Zdefiniowane produkty glikoproteinowe i powiązane sposoby

Country Status (12)

Country Link
US (2) US20100113294A1 (pl)
EP (2) EP2528002B1 (pl)
JP (1) JP2010524467A (pl)
CN (1) CN101681396A (pl)
AU (1) AU2008240080A1 (pl)
BR (1) BRPI0810471A2 (pl)
CA (1) CA2682738A1 (pl)
ES (1) ES2389618T3 (pl)
PL (1) PL2137655T3 (pl)
PT (1) PT2137655E (pl)
RU (1) RU2009141965A (pl)
WO (1) WO2008128227A1 (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MX353340B (es) 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
EP2325296A1 (en) * 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
CA2794709A1 (en) * 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. Selection and use of host cells for production of glycoproteins
CA2794697A1 (en) 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. High mannose glycans
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
WO2013114167A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of obtaining glycoform composition
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20150141620A1 (en) * 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to rituximab
EP2856159A4 (en) * 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS RELATING TO DENOSUMAB
US20150140608A1 (en) * 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
US20150158943A1 (en) * 2012-06-01 2015-06-11 Momenta Pharmaceuticals, Inc. Methods related to adalimumab
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
EP2991666B1 (en) * 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015069943A1 (en) * 2013-11-06 2015-05-14 L & J Biosciences Inc. Continuously controlled hollow fiber bioreactor
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2943667C (en) * 2014-01-29 2022-11-08 Lg Life Sciences Ltd. Method for modulating galactosylation of recombinant protein through optimization of culture medium
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
WO2017072201A2 (en) 2015-10-26 2017-05-04 Lonza Limited A manufacturing facility for the production of biopharmaceuticals
EP4310503A3 (en) 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Methods related to biologics
US11377677B2 (en) 2016-03-02 2022-07-05 Lonza Ltd Fermentation process
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
AU2017230823A1 (en) 2016-03-10 2018-09-27 Lonza Ltd Customizable facility
MX2018014681A (es) 2016-06-03 2019-06-06 Lonza Ag Biorreactor de un solo uso.
EP3469091A1 (en) 2016-06-10 2019-04-17 Lonza Ltd Method for stabilizing proteins
KR20190022711A (ko) 2016-06-24 2019-03-06 론자 리미티드 가변 직경 생물 반응기
EP3478821A1 (en) 2016-08-02 2019-05-08 Lonza Ltd Customizable facility
US20200054972A1 (en) 2016-11-17 2020-02-20 Andrew Bryce Filter assembly with filter lock design
WO2018092000A1 (en) 2016-11-17 2018-05-24 Lonza Ltd. Filter moving device
EP3535047A1 (en) 2016-12-09 2019-09-11 Lonza Ltd Method for the reduction of viral titer in pharmaceuticals
WO2018107067A1 (en) 2016-12-09 2018-06-14 Lonza Ltd Rupture disks for bioreactors and methods of using same
JP2020505059A (ja) 2017-01-18 2020-02-20 ロンザ リミテッドLonza Limited 単クローン性を評価するための方法
US20190360980A1 (en) 2017-02-03 2019-11-28 Lonza Ltd Methods of analyzing pluralities of cells and detecting protein sequence variants in biological product manufacturing
JP2020505940A (ja) 2017-02-10 2020-02-27 ロンザ リミテッドLonza Limited 細胞培養システム及び方法
WO2018150269A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
US11781116B2 (en) 2017-02-17 2023-10-10 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
US20190382718A1 (en) 2017-02-17 2019-12-19 Lonza Ltd A method for producing biologic product variants
US10244406B2 (en) 2017-03-07 2019-03-26 Lonza Ltd. Wireless sensor information monitoring
US12054733B2 (en) 2017-06-16 2024-08-06 Lonza Ltd Universal self-regulating mammalian cell line platform for the production of biologics
IL273548B2 (en) 2017-09-29 2025-01-01 Lonza Ag Perfusion device for use in bioreactor systems
EP3692358A1 (en) 2017-10-06 2020-08-12 Lonza Ltd Automated control of cell culture using raman spectroscopy
CA3083124A1 (en) 2017-11-20 2019-05-23 Lonza Ltd. Process and system for propagating cell cultures while preventing lactate accumulation
CN108052801B (zh) * 2017-11-30 2020-06-26 中国科学院计算技术研究所 一种基于正则表达式的n糖结构库构建方法与系统
WO2019113050A1 (en) 2017-12-05 2019-06-13 Lonza Ltd Methods of assaying tropolone
ES2871818T3 (es) 2018-02-02 2021-11-02 Lonza Ag Métodos de selección celular y modificación del metabolismo celular
CN119639849A (zh) 2018-03-26 2025-03-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
US12071607B2 (en) 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
KR20210030949A (ko) 2018-07-13 2021-03-18 론자 리미티드 내인성 단백질의 수준을 감소시켜 생물학적 생성물의 생산을 개선하는 방법
WO2020028616A1 (en) 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
WO2020031115A1 (en) 2018-08-09 2020-02-13 Lonza Ltd. Transfer station for api seed crystals
EP3833688A1 (en) * 2018-08-10 2021-06-16 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
US11568955B2 (en) 2018-08-21 2023-01-31 Lonza Ltd Process for creating reference data for predicting concentrations of quality attributes
JP7571010B2 (ja) 2018-09-06 2024-10-22 モメンタ ファーマシューティカルズ インコーポレイテッド 連続細胞培養の方法
US20220049275A1 (en) 2018-10-01 2022-02-17 Lonza, Ltd. Ssi cells with predictable and stable transgene expression and methods of formation
BR112021006852A2 (pt) 2018-10-11 2021-08-17 Momenta Pharmaceuticals, Inc. tratamento com composições de igg altamente sialilada
AU2019419372B2 (en) 2018-12-31 2026-03-26 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
KR20210126015A (ko) 2019-02-11 2021-10-19 론자 리미티드 완충제 제형화 방법 및 시스템
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
US20220389363A1 (en) 2020-01-10 2022-12-08 Lonza Walkersville, Inc. Filter Apparatus and Method for Purifying Biological Processes and Cell Populations
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
KR20230122078A (ko) 2020-12-18 2023-08-22 론자 바이올로직스 인크 바이오프로세스 시스템을 위한 멸균 단절기 및 이의사용 방법

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448884A (en) 1982-03-03 1984-05-15 Kms Fusion, Inc. Glass-surface microcarrier for growth of cell cultures
US5135853A (en) 1983-07-22 1992-08-04 Rensselaer Polytechnic Institute Three compartment bioreactor and method of use
US4764471A (en) 1984-01-04 1988-08-16 Nabisco Brands, Inc. Continuous bioreactor and process
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5231185A (en) 1985-11-19 1993-07-27 Cornell Research Foundation, Inc. Monosaccharide analog-based glycosidase inhibitors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
JPH0667317B2 (ja) * 1988-09-21 1994-08-31 財団法人野田産業科学研究所 N−アセチルヘキソサミンデヒドロゲナーゼ、その製造法及び該酵素を用いるn−アセチルグルコサミン又はn−アセチルガラクトサミンの定量法及びその定量用キット
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
CZ288492B6 (en) 1990-04-24 2001-06-13 Biota Scient Management Derivatives of alpha-D-neuraminic acid, process of their preparation, their use and pharmaceutical preparations based thereon
AU668505B2 (en) 1991-03-18 1996-05-09 Scripps Research Institute, The Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP0785988A1 (en) * 1993-07-15 1997-07-30 Neose Pharmaceuticals, Inc Method of synthesizing saccharide compositions
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
TW479061B (en) 1993-12-24 2002-03-11 Mitsubishi Chem Corp Sialic acid derivatives
US5567684A (en) 1994-09-14 1996-10-22 The Regents Of The University Of California Synthetic ganglioside derivatives
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
HUP0101355A3 (en) 1998-05-07 2003-08-28 Transkaryotic Therapies Inc Ca Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
CN1308673A (zh) 1998-05-07 2001-08-15 变更染色体医疗公司 通过同源重组修饰FSHβ基因的表达
US6949372B2 (en) * 1999-03-02 2005-09-27 The Johns Hopkins University Engineering intracellular sialylation pathways
ATE348173T1 (de) * 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
WO2001048147A1 (en) 1999-12-28 2001-07-05 Iso Tis N.V. Cell culture medium containing growth factors and l-glutamine
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
EP1298217A4 (en) * 2000-07-05 2004-09-08 Mitsubishi Pharma Corp Process for the production of a glycoprotein
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6544788B2 (en) 2001-02-15 2003-04-08 Vijay Singh Disposable perfusion bioreactor for cell culture
WO2002076578A1 (en) * 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
WO2003025133A2 (en) * 2001-09-14 2003-03-27 Mimeon, Inc. Methods of making glycolmolecules with enhanced activities and uses thereof
KR100988949B1 (ko) * 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003093430A2 (en) 2002-05-03 2003-11-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing sirnas
US7700758B2 (en) 2002-08-12 2010-04-20 New England Biolabs, Inc. Methods and compositions relating to gene silencing
EP1467299A3 (en) * 2003-03-28 2005-02-09 Solutia Inc. Methods and structure for automated active pharmaceuticals development
NZ542586A (en) * 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US7407810B2 (en) 2003-09-04 2008-08-05 Momenta Pharmaceuticals, Inc. Methods and apparatus for characterizing polymeric mixtures
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20060252672A1 (en) * 2005-04-05 2006-11-09 Betenbaugh Michael J Protein N-glycosylation of eukaryotic cells using dolichol-linked oligosaccharide synthesis pathway, other N-gylosylation-increasing methods, and engineered hosts expressing products with increased N-glycosylation
WO2006109781A1 (ja) * 2005-04-11 2006-10-19 Kyowa Hakko Kogyo Co., Ltd. 糖タンパク質組成物の製造方法
US8759005B2 (en) * 2005-07-11 2014-06-24 Glykos Finland Oy Tissue carbohydrate compositions and analysis thereof
US20070017758A1 (en) * 2005-07-20 2007-01-25 Or Siu W Magnetorheological damper and use thereof
DE202006008733U1 (de) * 2006-05-31 2007-10-11 Dolmar Gmbh Bremsbandhalterung
EP2035034A4 (en) * 2006-06-09 2009-11-18 Univ Maryland GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY
AU2007264846A1 (en) * 2006-06-29 2008-01-03 Glykos Finland Oy Novel cellular glycan compositions
MX353340B (es) * 2006-09-13 2018-01-09 Abbvie Inc Mejoras de cultivos celulares.
NZ613356A (en) * 2006-10-27 2015-02-27 Abbvie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
GB0624092D0 (en) * 2006-12-01 2007-01-10 Seos Ltd Image display apparatus
WO2008077889A1 (en) * 2006-12-22 2008-07-03 Ares Trading S.A. Analytical method for analyzing c-terminus truncation
EP2134853B1 (en) * 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation of molecules
ES2626080T3 (es) * 2007-04-16 2017-07-21 Momenta Pharmaceuticals, Inc. Caracterización de N-glicanos utilizando exoglicosidasas
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
CN102216452B (zh) * 2008-09-26 2013-08-21 尤里卡治疗公司 具有变异糖基化方式的细胞系和蛋白质
US11520643B2 (en) * 2008-12-03 2022-12-06 International Business Machines Corporation Clipboard object sharing for instant messaging
JP4892051B2 (ja) * 2009-11-30 2012-03-07 株式会社東芝 電子機器、及び機能設定データ設定方法
US8524217B2 (en) * 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) * 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture

Also Published As

Publication number Publication date
JP2010524467A (ja) 2010-07-22
AU2008240080A1 (en) 2008-10-23
CA2682738A1 (en) 2008-10-23
EP2528002A2 (en) 2012-11-28
EP2137655A1 (en) 2009-12-30
PT2137655E (pt) 2012-09-14
CN101681396A (zh) 2010-03-24
US20160097074A1 (en) 2016-04-07
ES2389618T3 (es) 2012-10-29
US20100113294A1 (en) 2010-05-06
EP2137655B1 (en) 2012-07-11
WO2008128227A1 (en) 2008-10-23
EP2528002A3 (en) 2013-04-03
RU2009141965A (ru) 2011-05-27
EP2528002B1 (en) 2015-11-04
BRPI0810471A2 (pt) 2014-11-11

Similar Documents

Publication Publication Date Title
BRPI0810471A2 (pt) Produtos de glicoproteína definidos e métodos relacionados
GB0813709D0 (en) Method and product
GB2453308B (en) Composite products
GB0723255D0 (en) Process and product
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
ZA201100373B (en) Cover and related products,and production thereof
EP2193097A4 (en) NANOSTRUCTURE IMPROVED COMPOSITE MATERIALS AND METHOD
GB0815534D0 (en) Process and product
GB0819720D0 (en) Methods and products
GB0809921D0 (en) Product and process therefor
GB0823012D0 (en) Process and product thereof
GB0813687D0 (en) Article and associated method
GB0921001D0 (en) Products and uses
GB0805473D0 (en) Method and article
GB0819883D0 (en) Product and uses
GB0812933D0 (en) Novel products and method
EP2124651A4 (en) PRODUCT AND METHOD FOR DRYING MEAT
GB2455897B (en) Cosmetic products
ZA200902899B (en) Product and process
EP2145245A4 (en) DIGITAL PAPER PRODUCTS AND METHODS CONNECTED THEREWITH
GB0714389D0 (en) Process and product
GB0618706D0 (en) Products
GB0608966D0 (en) Method and product
GB201021694D0 (en) Process and Product Thereof
GB0921525D0 (en) Product and method